Release Date: 27 May 2025
Multispecific antibodies constitute a revolutionary leap forward in the science of immunotherapy, providing a highly versatile platform for more effective and targeted cancer therapy. Engineered proteins that bind two or more different a...
Release Date: 16 May 2025
The global trispecific antibody market is currently in its developmental phase, with no approved products yet, though many candidates are advancing through clinical trials. These antibodies, which target three distinct an...
Release Date: 15 May 2025
In recent years, the advancement of pharmaceuticals aimed at rare cancers has significantly increased in the US, indicating a broader transition in the pharmaceutical industry towards precision medicine and targeted treat...
Release Date: 15 May 2025
US rare disease drug market has seen huge growth in the last few years, fueled by growing interest from pharmaceutical firms as well as regulators in rare diseases. With more than 500 FDA approved rare disease drugs curre...
Release Date: 02 April 2025
Personalized cancer vaccines are poised to reshape the landscape of oncology, offering a revolutionary approach to cancer treatment. By leveraging the unique characteristics of a patient’s tumor, these vaccines prov...
Release Date: 21 February 2025
Contract Research Organizations (CROs) play a vital role in advancing clinical trials in Saudi Arabia, serving as strategic partners for pharmaceutical companies looking to expand their presence in the region. With extens...
Release Date: 11 February 2025
Molecular switches are integral components of cellular signaling pathways that regulate various biological functions, including cell growth, apoptosis, immune response, and metabolism. In cancer, aberrant activation or su...
Release Date: 11 February 2025
In 2024, Imdelltra, a DLL3 andtimes; CD3 bispecific antibody for extensive-stage small cell lung cancer (ES-SCLC), achieved sales of US$ 115 million following its approval in May 2024. Despite being a newly launched thera...
Release Date: 11 February 2025
In 2024, Roche’s Hemlibra, a bispecific antibody for hemophilia A, achieved sales of over US$ 4.9 billion, marking an 8.6% increase from US$ 4.5 billion in 2023. This growth solidifies its position as the highest-se...
Release Date: 11 February 2025
In 2024, Roche’s Vabysmo, a bispecific antibody designed for ophthalmic use, achieved sales exceeding US$ 4.2 billion, reflecting a significant increase from approximately US$ 2.6 billion in 2023. This impressive gr...
Release Date: 11 February 2025
In 2024, Blincyto, a bispecific antibody, achieved sales of US$ 1.22 billion, marking a 41% increase from its 2023 sales of US$ 861 million. This milestone represents the first time Blincyto has crossed the US$ 1 billion ...
Release Date: 11 February 2025
In 2024, Elrexfio, a bispecific antibody developed by Pfizer for multiple myeloma, achieved sales of US$ 133 million, marking an increase of over 1,200% from its 2023 sales of approximately US$ 10 million. This represents...
Release Date: 11 February 2025
In 2024, Roche’s Columvi, a bispecific antibody for lymphoma, recorded sales of over US$ 188 million, marking an exceptional growth of over 500% from US$ 30 million in 2023. This surge represents one of the largest ...
Release Date: 11 February 2025
In 2024, Roche’s Lunsumio, a bispecific antibody for lymphoma, generated US$ 77 million in sales, reflecting a 22% increase from approximately US$ 64 million in 2023. The drug’s steady growth highlights its increasing adoption in the trea...
Release Date: 11 February 2025
CD39, an ectonucleotidase involved in the adenosine pathway, has gained attention as a therapeutic target in cancer immunotherapy due to its role in tumor-induced immunosuppression. By converting extracellular ATP into AM...